Full-Time

Director – Epidemiology & RWE Sciences

Ipsen Global

Ipsen Global

5,001-10,000 employees

Global biopharma focused on specialty care

Compensation Overview

$177k - $259.6k/yr

+ Short-term incentives + Long-term incentives

Cambridge, MA, USA

In Person

On-site role in Cambridge, Massachusetts; remote options not stated.

Category
Biology & Biotech (1)
Required Skills
SAS
R
Machine Learning

Get referred to Ipsen Global

See people who can refer or advise you

Requirements
  • Minimum 8-10 years of biotech/pharmaceutical experience in an Epidemiology, clinical Real-World Evidence (RWE) or outcomes research role within the pharmaceutical, biotechnology, or healthcare research environment
  • Strong methodological and analytical skills
  • Knowledge of medical, regulatory, and payor systems in one or more regions of the world
  • Demonstrated experience in designing and conducting pharmaco-epidemiology studies in support of pre-/post-approval evidence generating activities
  • Demonstrated experience applying innovative methodologies and modern analytic approaches to RWE, ideally in oncology or specialty diseases
  • Expert in data collection methods and strong familiarity with secondary data sources
  • Experience leading external analytic and evidence generating activities
  • Excellent data analytic skills, including knowledge of standard statistical software and packages (SAS, R, etc.)
  • Demonstrated ability to provide strong direct global project management/leadership skills
  • Exceptional critical thinking to identify gaps, analyze findings and make recommendations with clear next steps
  • Core strategy and analysis skills, with ability to lead and influence as a strategic partner to medical leaders
  • Ability to collaborate in a matrix and remote organizations
  • Ability to work, lead and thrive in a cross-functional team environment
  • Ability to work independently and as an active member within cross-functional teams
  • Experience in innovative and design thinking
  • Cross-cultural awareness
  • Excellent verbal communication, written, interpersonal, presentation and influencing skills
  • Ability to prioritize effectively
  • Education / Certifications (essential)
  • Advanced degree in Epidemiology, Public Health, Health Outcomes Research, Pharmacoepidemiology, Biostatistics, Medicine (MD), or a related scientific discipline required
  • PhD or MD/MPH strongly preferred
  • Language(s) (essential)
  • Fluent in English
Responsibilities
  • Partner effectively across the enterprise to support the identified evidence needs across Oncology and play a central role in designing Integrated Evidence Generation Plans (IEGPs) that address evidence gaps and contribute to the global Integrated Data and Evidence vision at Ipsen, ensuring alignment with product strategy, disease area priorities, and Ipsen’s broader evidence generation objectives
  • Provide strategic input to shape evidence that addresses regulatory, HTA, payer, clinician, and patient needs
  • In partnership with the Asset Teams, drive the RWE strategy per asset as part of IEGPs
  • Conduct critical review of RWE/Epidemiology studies designed by external service providers and/or cross-functional partners to ensure scientific robustness and alignment with strategic goals
  • Ensure the fulfilment of timely, high-quality epidemiology/RWE sections of Regulatory documents for agencies worldwide, including submissions, RMPs, breakthrough or orphan designations, advisory committee briefing books, etc.
  • Support External Innovation and Business Development teams in assessment of external licensing opportunities by providing timely disease population assessments
  • Partner with Clinical Development teams to provide Epi support for study design and planning activities
  • Engage externally with academic collaborators, patient registries, data partners, and methodological experts to advance Ipsen’s evidence capabilities and scientific reputation
  • Develop and review study protocols and statistical analysis plans in collaboration with Biometry, Medical and other internal stakeholders
  • Stay informed and involved on the latest regulatory and methodological advances that expand and enhance the utility of RWE
  • Educate and raise the awareness around epidemiologic methods and RWE and its potential in supporting Ipsen’s internal teams to generate buy-in across the organization
  • Mentor and provide functional leadership to RWE and evidence generation team members as applicable
  • Design prospective and retrospective pharmaco-epidemiology studies (including RWE studies) in the pre-/post-launch setting, including related to Regulatory post-approval commitments
  • Develop and adopt robust, fit-for-purpose data generation and analytic methodologies that advance research goals across different life cycle management stages
  • Drive the adoption of modern RWE methodologies and analytic techniques to generate impactful evidence in settings where conventional approaches may be limited
  • Apply and champion innovative study designs and modern analytics, such as pragmatic approaches, hybrid designs, external control arms, advanced causal inference methods, and longitudinal disease modeling, as appropriate
  • Oversee vendor-led and internally led RWE studies, including protocol development, study governance, timelines, quality, and budgets
  • Ensure methodological rigor while balancing scientific innovation, feasibility, and regulatory acceptability in oncological or rare disease contexts
  • Leverage contemporary data analytic methods (e.g., advanced statistical modeling, real-world data enrichment, linkage of disparate data sources, and exploratory use of machine-learning-enabled approaches where appropriate) to generate novel insights
  • Partner with Biostatistics, Data Science, and external vendors to ensure appropriate application and interpretation of advanced analytics within RWE studies
  • Provide budget input for activities related to Epidemiology and RWE studies and initiatives ensuring projects are adequately resourced
  • Ensure all RWE activities comply with internal SOPs, global regulations, data privacy requirements, and ethical standards
  • Actively participate in review of study proposals
  • Provide seamless and consistent support to global and local franchises
  • Ensure linkage of study data and insights gathered from external experts, including HCPs and patient organisations, in close continuous partnership with Medical Asset Leads and Therapy Areas
  • Fully involve Ipsen stakeholders (GMA TAs, HEOR, GMA Clin Ops, GMPC, R&D and affiliates) in the design and implementation of the RWE framework utilizing strong communication skills
  • Ensure Ipsen can provide comprehensive patient focussed data & analytics in the disease areas we serve
  • Drive Medical, cross-functional and global alignment to enable early strategic alignment of Medical Affairs
  • Epidemiology and RWE studies across global and local teams, in partnership with the Medical Asset Leads, to ensure late phase data generation plans maximise data availability, ensure patient impact and effective execution of RWE programs
  • Establish end-to-end best practices for data generation and sharing (policy, SOP, Legal, Privacy, etc.)

Ipsen is a global biopharmaceutical company that concentrates on specialty care, developing and marketing medicines for oncology, neuroscience, and rare diseases. Its products work by treating specific high-need conditions, ranging from historical diarrhea treatment Smecta to modern targeted therapies in cancer and neurological disorders. The company differentiates itself through a focused portfolio in niche therapeutic areas, growth via strategic acquisitions, and a long-standing family heritage that shaped its international expansion and IPO-driven capital for expansion. Its goal is to address unmet medical needs worldwide by providing effective therapies for patients with serious or rare conditions.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boulogne-Billancourt, France

Founded

2005

Get referred to Ipsen Global

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Bylvay generated €180 million in 2025, up 32.5% year over year.
  • Ojemda's EU assessment provides a reusable template for broader reimbursement submissions.
  • Ipsen's specialty-care focus targets high-value, unmet-need markets with durable pricing power.

What critics are saying

  • Bylvay's Phase III failure eliminates a biliary atresia expansion opportunity.
  • Ojemda still faces country-by-country reimbursement fights after the EU clinical assessment.
  • Ipsen's growth remains exposed to binary trial outcomes in concentrated therapeutic areas.

What makes Ipsen Global unique

  • Founded in 1929, Ipsen focuses on oncology, rare disease, and neuroscience.
  • Ipsen built specialty care through Smecta, Decapeptyl, and later global expansion.
  • The company combines French heritage with international R&D and commercial operations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Flexible Work Hours

Hybrid Work Options

Remote Work Options

Paid Vacation

Company News

MarketScreener
Apr 7th, 2026
Beech Tree wins AMF waiver exempting it from mandatory takeover bid for 26% Ipsen stake

French pharmaceutical company Ipsen has announced that Beech Tree, which holds a 26.03% stake in the company's capital and 33.05% of voting rights, has received a waiver from the French Financial Markets Authority exempting it from filing a mandatory public tender offer. The waiver follows the transfer of Henri Beaufour's stake in Beech Tree to the Alasol Foundation. The transaction includes a governance agreement between Altawin, the Alasol Foundation and Beech Tree. Under the agreement, the Alasol Foundation has committed to holding its Beech Tree shares for at least 15 years and will not interfere in Beech Tree's management of its Ipsen stake. The agreement also establishes Altawin's veto rights and ensures continuity with the strategic direction set during Beaufour's lifetime.

Chinook Observer
Mar 18th, 2026
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR.

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR. GlobeNewswire | Ipsen Pharma Yesterday at 11:00pm PDT * IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors * ITGA2 revealed as novel target of Ipsen's investigational antibody drug conjugate IPN60300, over-expressed across numerous solid tumor types * Preclinical data show potential of Ipsen's growing collection of investigational medicines, leveraging precision immuno-modulation to deliver differentiated anti-tumor activity PARIS, FRANCE, 18 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of new preclinical data across multiple early development programs currently in Phase I clinical trials, at the American Association of Cancer Research (AACR) congress. These latest data include an oral presentation for T cell activator (TCA) IPN01203 to be presented during the coveted New Drugs on the Horizon program session, highlighting the differentiated mode of action, activating Vβ6/Vβ10 T cells. These latest preclinical data will expand the growing evidence base, reinforcing the first-in-class potential of IPN01203 to improve outcomes where there are significant unmet needs for people living with solid tumors. Additionally, Ipsen revealed ITGA2 as the novel target for innovative antibody-drug conjugate (ADC) IPN60300, now in active Phase I evaluation. Preclinical findings showed pronounced over-expression of ITGA2 across multiple solid tumors - including pancreatic, gastric and colorectal cancers - with clear differential expression when compared to normal tissues. These results confirmed that IPN60300 binds specifically and with high affinity to ITGA2, enabling efficient internalization and accumulation of the exatecan payload. Further preclinical tumor model data showed dose-dependent anti-tumor activity and favorable tolerability, suggesting a promising first-in-class therapy with the potential to improve clinical outcomes. "These data presented at AACR exemplify our approach to early science, showcasing how we are harnessing precision immuno-modulation backed by the strength of preclinical data to advance next generation therapies where there are the highest unmet needs," said Mary Jane Hinrichs, SVP Early Development, Ipsen. "It's a privilege to see the growing transformative potential of these new modalities, paving the way for potential best- and first-in-class impact for people living with cancer." Underscoring the strength and promise of Ipsen's precision medicine approach, IPN01203 and IPN60300 combine precision targeting with innovative mechanisms of action with the aim of delivering strength of efficacy where few other treatments exist. About IPN01203 IPN01203 is a first-in-class T cell activator which selectively activates a group of Vβ6 T cells through the TCR and IL-15R pathways, enhancing their ability to recognize and target tumors. IPN01203 was generated by Marengo's Selective T Cell Activation Repertoire (STAR) platform, a multi-specific fusion protein library that targets specific TCR Vβ variants fused to different co-stimulate moieties to develop potent T cell activators. A Phase I/II dose escalation and expansion trial is ongoing. About IPN60300 IPN60300 is a first-in-class antibody-drug conjugate targeting the novel tumor antigen ITGA2 known to be overexpressed in many solid tumors, including pancreatic, gastric and colorectal cancers. This novel tumor antigen was identified using Foreseen' Biotechnology's high throughput, integrated translational proteomics, and artificial intelligence (AI)-powered screening platforms. Comprised of an ITGA2-targeting antibody, exatecan payload and innovative linker from Escugen Biotechnology's EZWi-Fit(TM), IPN60300 is optimally designed to allow for a wide therapeutic index, with potential for improved efficacy over standard of care as well as a favorable safety profile. A Phase I/II dose escalation and expansion trial is ongoing. About Ipsen Chinook Observer is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Its pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Its teams in more than 40 countries and its partnerships around the world enable Chinook Observer to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. | Ipsen Contacts | / | / | | Investors | / | / | | Henry Wheeler | [email protected] | +33 7 66 47 11 49 | | Khalid Deojee | [email protected] | +33 6 66 01 95 26 | | Media | / | / | | Sally Bain | [email protected] | +1 857 320 0517 | | Anne Liontas | [email protected] | +33 7 67 34 72 96 | | / | / | / | Disclaimers and/or forward-looking statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on ipsen.com. This is a paid placement. For further inquiries, please contact GlobeNewswire directly.

EQT Group
Oct 22nd, 2025
EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion

· Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agreement. ImCheck’s shareholders will be eligible to receive a payment of EUR 350 million and downstream payments,  for a total potential consideration of up to EUR 1 billion. · ImCheck Therapeutics is a private French biotechnology company pioneering next-generation immuno-oncology therapies. · EQT Life Sciences has backed ImCheck since 2017 and has provided comprehensive support beyond capital, at the board level.

GlobeNewswire
Mar 19th, 2025
Ipsen announces issuance of €500 million inaugural Rated Public Bond

Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a...

Business Wire
Jun 9th, 2023
BAKX Raises $25 Million to Develop Therapeutics Targeting Pro-Apoptotic Proteins and Mitochondrial Apoptosis Pathway

BAKX Therapeutics today announced it closed $25 million in a Series A fundraising led by AB Magnitude Ventures Group with Ipsen Pharma SA and Sherpa H